(Q80523138)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

title

[Use and cost of biological disease-modifying anti-rheumatic drugs in Spain (PRAXIS study)] (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

author name string

C Rubio-Terrés

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

J P Ordovás Baines

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

R Pla Poblador

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

C Martínez Nieto

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

M J Sánchez Garre

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

M A Rosado Souvirón

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Ana Sierra Muñoz

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Miriam Sánchez Mateo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

Grupo de Investigadores del Estudio PRAXIS

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

publication date

1 March 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria

1 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

page(s)

78-92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

The burden of musculoskeletal diseases in the general population of Spain: results from a national survey

1 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975718-5

7 January 2021

Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975718-5

7 January 2021

[Cost analysis in a cohort of rheumatoid arthritis patients managed in rheumatology units in Spain].

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975718-5

7 January 2021

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975718-5

7 January 2021

Treatment continuation in patients receiving biological agents or conventional DMARD therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975718-5

7 January 2021

The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975718-5

7 January 2021

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975718-5

7 January 2021

Métodos utilizados para realizar evaluaciones económicas de intervenciones sanitarias

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975718-5

7 January 2021

Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975718-5

7 January 2021

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1130-6343%2807%2975718-5

7 January 2021

10.1016/S1130-6343(07)75718-5

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17590116%20AND%20SRC:MED&resulttype=core&format=json

1 January 2020

1 reference